GRI Bio, Inc. cotiza a 1.57 USD y tiene una capitalización bursátil de $3M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, …
| Periodo | 2026-05 | 2026-01 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-1.61 | $-116.61 | $-35.84 | $-36.68 |
| Estimado | $-3.74 | $-29.26 | $-31.08 | $-36.68 |
| Sorpresa | +57.0% | -298.5% | -15.3% | +0.0% |
| Métrica | GRI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -199.0% | -40.4% | -158.6% |
| ROA | -138.0% | -32.0% | -106.0% |
| Current Ratio | 3.25 | 2.84 | +0.41 |
| Debt / Equity | — | 0.28 | — |